PMGC Holdings Stock Price, News & Analysis
Company Description
PMGC Holdings Inc. is a Nasdaq-listed holding company that owns and develops operating subsidiaries across precision manufacturing, aerospace and defense supply-chain services, industrial packaging, defense technology, and bioscience assets. The company trades under the symbol ELAB and is organized as a Nevada corporation headquartered in Newport Beach, California. Its recent corporate profile centers on building a diversified platform of U.S.-based manufacturing and technology businesses while retaining biotechnology assets focused on muscle health and metabolic-related applications.
PMGC’s manufacturing platform includes precision CNC machining businesses that supply components for aerospace, defense, industrial, and related programs. Subsidiaries referenced in company disclosures include AGA Precision Systems LLC, an ITAR-registered and AS9100-certified precision CNC aerospace and defense manufacturer, and SVM Machining, Inc., which does business as Silicon Valley Manufacturing and is described as an ISO 9001:2015 certified precision CNC machining company. These subsidiaries support customer programs through long-term agreement frameworks and future purchase orders for mission-critical components.
The company also owns Pacific Sun Packaging, Inc., a packaging solutions provider specializing in custom-engineered packaging for electronics and information technology hardware. Pacific Sun Packaging serves markets tied to data centers, technology manufacturers, IT service providers, IT asset disposition, reverse logistics, circular electronics, and e-waste management supply chains. This business broadens PMGC’s manufacturing exposure beyond machined components into specialty packaging for hardware and technology infrastructure customers.
PMGC’s bioscience activities are conducted through NorthStrive Biosciences Inc., a wholly owned subsidiary developing engineered probiotic assets. NorthStrive’s lead asset, EL-22, is described as a proprietary myostatin-engineered probiotic being developed for muscle preservation and growth applications, including muscle loss associated with GLP-1 receptor agonist therapy, sarcopenia, muscle disuse atrophy, and certain neurological disorders. The subsidiary has also disclosed work involving EL-32, a next-generation engineered probiotic asset targeting myostatin and Activin-A pathways across human and animal health applications.
PMGC has also formed NorthStrive Defense Tech LLC, a wholly owned subsidiary associated with defense technology initiatives. Company disclosures describe defense-related activities involving autonomous navigation, counter-unmanned aircraft systems, electronic warfare, and GPS-denied operating environments, alongside evaluation and potential commercialization processes for protected technologies.
The company’s business model combines holding-company ownership, acquisition-led platform building, subsidiary-level customer agreements, and development of technology and intellectual property assets. Its disclosed capital actions include equity financing arrangements intended to support acquisitions and organic investment across aerospace, defense, industrial manufacturing, and related operating areas. PMGC’s public-company profile therefore spans both operating subsidiaries with customer-facing manufacturing activities and development-stage assets that depend on intellectual property, manufacturing optimization, licensing, and future commercialization pathways.
Stock Performance
PMGC Holdings (ELAB) stock last traded at $2.08, down 1.46% from the previous close. Over the past 12 months, the stock has lost 99.0%. At a market capitalization of $9.2M, ELAB is classified as a micro-cap stock with approximately 4.5M shares outstanding.
ELAB Rankings
Latest News
PMGC Holdings has 10 recent news articles, with the latest published today. Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, acquisition, partnership. View all ELAB news →
SEC Filings
PMGC Holdings has filed 5 recent SEC filings, including 1 Form DEF 14A, 1 Form 10-Q, 1 Form 8-K, 1 Form PRE 14A. The most recent filing was submitted on May 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ELAB SEC filings →
Financial Highlights
PMGC Holdings generated $590K in revenue over the trailing twelve months, retaining a 31.4% gross margin, and net income was -$7.7M, reflecting a -1313.0% net profit margin. Diluted earnings per share stood at $-382.30. The company generated -$5.9M in operating cash flow. With a current ratio of 1.74, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in PMGC Holdings (ELAB) currently stands at 414.5 thousand shares, down 74.8% from the previous reporting period, representing 21.4% of the float. Over the past 12 months, short interest has increased by 366.1%. This high level of short interest suggests significant bearish sentiment among traders.
Days to Cover History
Days to cover for PMGC Holdings (ELAB) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 2.8 days.
ELAB Company Profile & Sector Positioning
PMGC Holdings (ELAB) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.
Investors comparing ELAB often look at related companies in the same sector, including Scisparc (SPRC), Revelation Biosciences (REVB), Qualigen Therapeutics Inc (QLGN), Unity Btech (UBX), and Indaptus Therapeutics Inc (INDP). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ELAB's relative position within its industry.